QRG Capital Management Inc. Raises Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

QRG Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 97.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,949 shares of the biopharmaceutical company's stock after acquiring an additional 964 shares during the quarter. QRG Capital Management Inc.'s holdings in Alnylam Pharmaceuticals were worth $526,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Whipplewood Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $28,000. Colonial Trust Co SC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $309.70 on Monday. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company's fifty day moving average price is $277.63 and its two-hundred day moving average price is $261.10. The firm has a market capitalization of $40.38 billion, a P/E ratio of -148.18 and a beta of 0.22. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $317.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALNY. Morgan Stanley dropped their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, UBS Group raised their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $319.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.